Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERCORTEN vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
Adjunctive therapy in adrenocortical insufficiency (Addison's disease) for mineralocorticoid replacement,Off-label: Treatment of orthostatic hypotension due to autonomic dysfunction
Treatment of hypophosphatemia,Total parenteral nutrition (TPN) additive,Phosphate replacement in patients with phosphate depletion
1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
Terminal elimination half-life is approximately 30-40 minutes. Clinically, the short half-life necessitates frequent dosing (e.g., every 6-12 hours) to maintain therapeutic effect in mineralocorticoid replacement.
Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation.
Primarily hepatic via reduction and conjugation; excreted in urine as metabolites. Desoxycorticosterone pivalate is a prodrug that is hydrolyzed to desoxycorticosterone, which is then metabolized.
Phosphate is freely filtered by the glomerulus and reabsorbed in the proximal tubule; excess is excreted renally. No significant hepatic metabolism.
Renal (biliary/fecal negligible). Approximately 50-70% of a dose is excreted as metabolites in urine; <5% unchanged.
Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss.
Approximately 90-94% bound to albumin and corticosteroid-binding globulin (CBG).
Phosphate: 10-15% bound to serum proteins (albumin and immunoglobulins). Potassium: <5% protein bound.
Vd approximately 0.5-0.8 L/kg. Clinical meaning: Distributes primarily into extracellular fluid; low Vd indicates limited tissue penetration.
Phosphate: 0.15-0.3 L/kg (primarily extracellular fluid). Potassium: 0.5-0.7 L/kg (distributes into intracellular space).
Oral: Approximately 50-70% (high first-pass metabolism). IM/SC: 100% (assumed).
Intravenous: 100% bioavailability. Oral (not applicable for this formulation): 60-70% for phosphate salts; potassium salts >90%.
No specific GFR-based dose adjustments established; use with caution in renal impairment due to potential for fluid retention and hypertension.
GFR <30 m L/min: initiate at 50% of standard dose and titrate based on serum phosphate and potassium levels; avoid if GFR <15 m L/min unless severe hypophosphatemia.
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment due to reduced metabolism and increased risk of adverse effects.
No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to potential for electrolyte disturbances.
0.1-0.3 mg/kg intramuscularly or subcutaneously daily, divided every 12-24 hours, with titration based on clinical response.
IV: 0.5-1 mmol phosphate/kg over 12-24 hours; monitor serum phosphate and potassium closely; do not exceed 5 mmol/kg/day.
Initiate at lower end of adult dose (1 mg daily) with careful monitoring for fluid overload and electrolyte disturbances due to age-related renal and cardiovascular changes.
Initiate at lower end of dosing range; monitor renal function and serum electrolytes more frequently due to age-related decline in GFR.
None
None
May cause severe hypertension, edema, congestive heart failure, hypokalemia, or metabolic alkalosis. Monitor blood pressure, serum electrolytes, and body weight. Use with caution in patients with cardiac disease, renal impairment, or hepatic disease. Avoid excessive sodium intake.
Hyperphosphatemia, especially in renal impairment,Hypocalcemia due to precipitation with calcium,Monitor serum calcium, phosphate, and renal function,Avoid extravasation (may cause tissue necrosis),Not for IV push; give as slow infusion
Hypersensitivity to desoxycorticosterone or any component,Severe hypertension,Hyperkalemia,Edema or fluid overload states,Congestive heart failure,Severe renal impairment
Hyperphosphatemia,Hypocalcemia,Renal failure (unless on dialysis),Patients with known hypersensitivity to any component
Avoid high-potassium foods (e.g., bananas, oranges, salt substitutes) as Percorten increases potassium retention. Limit sodium intake to manage fluid balance.
Avoid high-phosphate foods (e.g., dairy, nuts, seeds, whole grains, cola) and high-potassium foods (e.g., bananas, oranges, potatoes, spinach) unless prescribed. Limit intake of calcium-rich foods if calcium levels are low.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use during pregnancy only if clearly needed. First trimester: Possible increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: Potential for adrenal suppression in the fetus/newborn.
FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalcemia, electrolyte imbalances in fetus; avoid prolonged use.
Corticosteroids are excreted in breast milk in small amounts. Desoxycorticosterone pivalate specific data are lacking. M/P ratio not determined. At high maternal doses, monitor infant for signs of adrenal suppression. Use with caution.
Excretion in human milk unknown; M/P ratio not determined. Use with caution, weighing benefit against potential risk of electrolyte disturbances in the nursing infant.
Pregnancy may increase clearance of corticosteroids, potentially requiring dose adjustments. However, specific pharmacokinetic data for Percorten are lacking. Use lowest effective dose and monitor clinical response and serum levels if available.
Increased plasma volume may require higher doses to achieve therapeutic levels; monitor serum electrolytes closely to avoid hyperphosphatemia or hypocalcemia. No standard dose adjustment established.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid used for adrenal insufficiency. Monitor for hypertension, hypokalemia, and edema. Titrate dose based on blood pressure and serum potassium. Use with caution in heart failure or renal impairment.
Do not administer undiluted; must be infused via central line if concentration > 0.45% potassium phosphate. Monitor serum potassium, phosphate, calcium, and magnesium. Rate of infusion should not exceed 10 mmol/h of phosphate. Risk of hypocalcemia due to phosphate precipitation. Use with caution in renal impairment.
Take exactly as prescribed; do not miss doses.,Report rapid weight gain, swelling, or shortness of breath.,Avoid excessive salt intake; follow a low-sodium diet if advised.,Do not stop abruptly; taper under medical supervision.
This medication is given through a vein to restore phosphate and potassium levels.,Report any signs of infusion site pain, redness, or swelling.,Inform your healthcare provider if you experience muscle cramps, weakness, numbness, or tingling.,This medication may cause low calcium levels; report symptoms such as muscle spasms or confusion.,Do not consume additional potassium or phosphate supplements unless directed by your doctor.
No interactions on record
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERCORTEN vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, answered by our medical review team.
PERCORTEN is a Mineralocorticoid that works by Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERCORTEN and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERCORTEN is: 1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.. The standard adult dose of POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is: IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERCORTEN and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERCORTEN is classified as Category C. Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use duri. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is classified as Category A/B. FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalce. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.